Patient characteristic, n (%) | NAVIGATOR | Study 1002 n = 19 | P value | ||
---|---|---|---|---|---|
All doses n = 56 | 300/400 mg n = 38 | NAVIGATOR All doses vs Study 1002 | NAVIGATOR 300/400 mg vs Study 1002 | ||
Sex | 0.601 | 0.844 | |||
Male | 39 (70) | 25 (66) | 12 (63) | ||
Female | 17 (30) | 13 (34) | 7 (37) | ||
Agea | 0.046* | 0.088 | |||
< 60 years | 18 (32) | 13 (34) | 11 (58) | ||
≥ 60 years | 38 (68) | 25 (66) | 8 (42) | ||
Race | 0.101 | 0.042* | |||
White | 39 (78) | 25 (71) | 18 (95) | ||
Non-white | 11 (22) | 10 (29) | 1 (5) | ||
Missing | 6 | 3 | 0 | ||
Anatomical siteb | 0.757 | 0.823 | |||
Gastric (stomach) | 46 (82) | 29 (76) | 15 (79) | ||
Small bowel or rectal (any other organ) | 10 (18) | 9 (24) | 4 (21) | ||
Metastatic diseasea | 0.745 | 0.611 | |||
No | 2 (4) | 1 (3) | 1 (5) | ||
Yes | 54 (96) | 37 (97) | 18 (95) | ||
ECOG Performance Statusa | 0.445 | 0.400 | |||
0 | 21 (38) | 13 (34) | 1 (100) | ||
1 | 32 (57) | 23 (61) | 0 | ||
≥ 2 | 3 (5) | 2 (5) | 0 | ||
Missing | 0 | 0 | 18 | ||
Duration of diseasec | 0.386 | 0.340 | |||
< 3 years | 32 (57) | 21 (55) | 13 (68) | ||
≥ 3 years | 24 (43) | 17 (45) | 6 (32) | ||
Number of TKI treatment linesd | 0.124 | 0.040* | |||
1 | 11 (20) | 5 (13) | 3 (16) | ||
2 | 23 (41) | 20 (53) | 3 (16) | ||
3 | 9 (16) | 6 (16) | 4 (21) | ||
≥ 4 | 13 (23) | 7 (18) | 9 (47) |